Rocket Pharmaceuticals, Inc.
DE ˙ DB ˙ US77313F1066
2,44 € 0,00 (0,00%)
2026-06-04
CENA AKCJI
SecurityDE:9IP1 / Rocket Pharmaceuticals, Inc.
InstitutionVanguard Group Inc
Latest Disclosed Ownership8,544,423 shares
Ownership 7.89%
Vanguard Group Inc ownership in 9IP1 / Rocket Pharmaceuticals, Inc.

2026-01-30 - Vanguard Group Inc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 8,544,423 shares of Rocket Pharmaceuticals, Inc. (DE:9IP1). This represents 7.89 percent ownership of the company. In their previous filing dated 2024-02-13 , Vanguard Group Inc had reported owning 5,447,565 shares, indicating an increase of 56.85 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2026-01-30 2026-01-30 13G/A 5,447,565 8,544,423 56.85 7.89 30.63
2024-02-13 2024-02-13 13G/A 4,186,542 5,447,565 30.12 6.04 13.53
2023-02-09 2023-02-09 13G/A 3,301,138 4,186,542 26.82 5.32 3.91
2022-02-10 2022-02-10 13G 3,301,138 5.12

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-01-29 2025-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 8,544,423 1,652,219 23.97 29,991 33.48 0.0004
2025-11-07 2025-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 6,892,204 769,743 12.57 22,469 49.79 0.0003
2025-08-11 2025-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 6,122,461 -495,323 -7.48 15,000 -66.02 0.0002
2025-05-09 2025-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 6,617,784 40,189 0.61 44,141 -46.61 0.0008
2025-02-11 2024-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 6,577,595 1,040,655 18.79 82,680 -19.15 0.0014
2024-11-13 2024-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 5,536,940 -271,610 -4.68 102,267 -18.22 0.0018
2024-08-13 2024-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 5,808,550 437,665 8.15 125,058 -13.57 0.0024
2024-05-10 2024-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 5,370,885 -76,680 -1.41 144,692 -11.38 0.0029
2024-03-11 2023-12-31 13F/A-1 ROCKET PHARMACEUTICALS COM 77313F106 5,447,565 843,552 18.32 163,264 73.07 0.0036
2024-02-14 2023-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 5,447,565 843,552 163,264 0.0031
2023-12-18 2023-09-30 13F/A-1 ROCKET PHARMACEUTICALS COM 77313F106 4,604,013 4,085 0.09 94,336 3.21 0.0023
2023-11-14 2023-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 4,604,013 4,085 94,336 0.0004
2023-08-14 2023-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 4,599,928 67,504 1.49 91,401 17.72 0.0022
2023-07-14 2023-03-31 13F/A-1 ROCKET PHARMACEUTICALS COM 77313F106 4,532,424 345,882 8.26 77,640 -5.24 0.0020
2023-05-15 2023-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 4,532,424 345,882 77,640 0.0020
2023-02-10 2022-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 4,186,542 769,031 22.50 81,931 50.21 0.0022
2022-11-14 2022-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 3,417,511 62,020 1.85 54,544 18.13 0.0016
2022-08-12 2022-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 3,355,491 6,331 0.19 46,172 -13.08 0.0013
2022-05-13 2022-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 3,349,160 48,022 1.45 53,118 -26.29 0.0013
2022-02-14 2021-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 3,301,138 55,750 1.72 72,064 -25.71 0.0016
2021-11-12 2021-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 3,245,388 37,623 1.17 97,004 -31.72 0.0024
2021-08-13 2021-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 3,207,765 296,191 10.17 142,072 9.97 0.0035
2021-05-14 2021-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 2,911,574 874,115 42.90 129,186 15.62 0.0035
2021-02-12 2020-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 2,037,459 119,454 6.23 111,734 154.84 0.0032
2020-11-16 2020-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 1,918,005 -10,279 -0.53 43,844 8.64 0.0015
2020-08-14 2020-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 1,928,284 71,177 3.83 40,358 55.78 0.0014
2020-05-15 2020-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 1,857,107 59,707 3.32 25,907 -36.67 0.0011
2020-02-14 2019-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 1,797,400 248,613 16.05 40,908 126.71 0.0014
2019-11-14 2019-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 1,548,787 46,438 3.09 18,044 -19.93 0.0007
2019-08-14 2019-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 1,502,349 235,411 18.58 22,536 1.41 0.0008
2019-05-15 2019-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 1,266,938 129,868 11.42 22,223 31.87 0.0009
2019-02-14 2018-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 1,137,070 175,606 18.26 16,852 -28.81 0.0008
2018-12-13 2018-09-30 13F/A-2 ROCKET PHARMACEUTICALS COM 77313F106 961,464 112,180 13.21 23,671 41.99 0.0009
2018-11-23 2018-09-30 13F/A-1 ROCKET PHARMACEUTICALS COM 77313F106 961,464 0 23,671 0.0009
2018-11-14 2018-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 961,464 112,180 23,671
2018-08-14 2018-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 849,284 175,265 26.00 16,671 31.92 0.0007
2018-05-15 2018-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 674,019 -306,206 -31.24 12,637 393.83 0.0006
2018-02-14 2017-12-31 13F INOTEK PHARMACEUTICALS COM 45780V102 980,225 361,673 58.47 2,559 132.43 0.0001
2017-11-14 2017-09-30 13F INOTEK PHARMACEUTICALS COM 45780V102 618,552 301,839 95.30 1,101 82.89 0.0001
2017-08-24 2017-06-30 13F/A-1 INOTEK PHARMACEUTICALS COM 45780V102 316,713 -384,942 -54.86 602 -57.09 0.0000
2017-08-11 2017-06-30 13F INOTEK PHARMACEUTICALS COM 45780V102 316,713 -384,942 602
2017-05-12 2017-03-31 13F INOTEK PHARMACEUTICALS COM 45780V102 701,655 290,433 70.63 1,403 -44.06 0.0001
2017-02-14 2016-12-31 13F INOTEK PHARMACEUTICALS COM 45780V102 411,222 -205,434 -33.31 2,508 -57.10 0.0001
2016-11-14 2016-09-30 13F INOTEK PHARMACEUTICALS COM 45780V102 616,656 21,583 3.63 5,846 32.05 0.0003
2016-08-10 2016-06-30 13F INOTEK PHARMACEUTICALS COM 45780V102 595,073 67,557 12.81 4,427 13.43 0.0003
2016-05-13 2016-03-31 13F INOTEK PHARMACEUTICALS COM 45780V102 527,516 62,781 13.51 3,903 -25.88 0.0003
2016-02-08 2015-12-31 13F INOTEK PHARMACEUTICALS COM 45780V102 464,735 458,335 7,161.48 5,266 8,676.67 0.0004
2015-11-12 2015-09-30 13F/A-1 INOTEK PHARMACEUTICALS COM 45780V102 6,400 -27,300 -81.01 60 -63.64 0.0000
2015-11-12 2015-09-30 13F/A-1 INOTEK PHARMACEUTICALS COM 45780V102 810,320 776,620 7,616 0.0003
2015-11-12 2015-09-30 13F INOTEK PHARMACEUTICALS COM 45780V102 408,360 3,838
2015-08-13 2015-06-30 13F INOTEK PHARMACEUTICALS COM 45780V102 33,700 33,700 165 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.